Sandoz has secured a global license agreement with EirGenix Inc. to exclusively commercialize a proposed biosimilar of pertuzumab for treating HER2-positive breast cancer, reflecting a strategic move to enhance its oncology portfolio and patient access to affordable treatments.

Information on the Target

Sandoz, a global leader in affordable medicines, has entered into a global license agreement with EirGenix Inc. to commercialize a proposed biosimilar of pertuzumab, a treatment for HER2-positive early breast cancer and metastatic breast cancer. This agreement is milestone-based, with a total potential consideration of up to USD 152 million, which includes an upfront payment along with performance-related incentives. Pertuzumab is a humanized IgG1 monoclonal antibody that is typically used in conjunction with other therapies, making it a strategic addition to Sandoz’s expanding oncology portfolio.

The global market for the reference medicine is estimated to generate sales of USD 4.1 billion, highlighting the significant potential demand for affordable biosimilar alternatives. As the market transitions, the incorporation of pertuzumab into Sandoz's offerings aligns with their long-term strategy to tap into a projected USD 300 billion biosimilar market over the next decade.

Industry Overview in the Target’s Specific Country

Breast cancer is a prevalent health concern globally, with approximately 2.3 million new cases diagnosed each year. Among these, around 15% to 20% are classified as HER2-positive, a subtype that is particularly aggressive an